T. Rowe Price Associates’s Fulcrum Therapeutics FULC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $475K | Sell |
69,028
-1,140
| -2% | -$7.85K | ﹤0.01% | 2326 |
|
|
2025
Q1 | $203K | Buy |
70,168
+17,800
| +34% | +$51.5K | ﹤0.01% | 2626 |
|
|
2024
Q4 | $247K | Buy |
52,368
+16,656
| +47% | +$78.6K | ﹤0.01% | 2588 |
|
|
2024
Q3 | $128K | Hold |
35,712
| – | – | ﹤0.01% | 2773 |
|
|
2024
Q2 | $222K | Buy |
35,712
+19,812
| +125% | +$123K | ﹤0.01% | 2552 |
|
|
2024
Q1 | $151K | Hold |
15,900
| – | – | ﹤0.01% | 2693 |
|
|
2023
Q4 | $108K | Hold |
15,900
| – | – | ﹤0.01% | 2705 |
|
|
2023
Q3 | $71K | Sell |
15,900
-5,300
| -25% | -$23.7K | ﹤0.01% | 2719 |
|
|
2023
Q2 | $70K | Sell |
21,200
-15,261
| -42% | -$50.4K | ﹤0.01% | 2753 |
|
|
2023
Q1 | $104K | Sell |
36,461
-114,048
| -76% | -$325K | ﹤0.01% | 2679 |
|
|
2022
Q4 | $1.1M | Buy |
150,509
+105,904
| +237% | +$770K | ﹤0.01% | 1729 |
|
|
2022
Q3 | $361K | Buy |
44,605
+14,888
| +50% | +$120K | ﹤0.01% | 2289 |
|
|
2022
Q2 | $146K | Buy |
29,717
+4,512
| +18% | +$22.2K | ﹤0.01% | 2667 |
|
|
2022
Q1 | $596K | Sell |
25,205
-109,550
| -81% | -$2.59M | ﹤0.01% | 2255 |
|
|
2021
Q4 | $2.38M | Buy |
134,755
+90,355
| +204% | +$1.6M | ﹤0.01% | 1647 |
|
|
2021
Q3 | $1.25M | Buy |
+44,400
| New | +$1.25M | ﹤0.01% | 1931 |
|